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Tumour necrosis factor gene polymorphism: a predictive factor for
the development of post-transplant lymphoproliferative disease
KA McAulay*,1, T Haque2 and DH Crawford1
1Clinical and Basic Virology Laboratory, School of Biomedical Sciences, University of Edinburgh, Summerhall, Edinburgh EH9 1QH, UK; 2Centre for
Virology, UCL Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
BACKGROUND: Epstein–Barr virus-positive post-transplant lymphoproliferative disease (PTLD) is a potentially lethal complication of
iatrogenic immunosupression after transplantation. Predicting the development of PTLD allowing early and effective intervention is
therefore of importance. Polymorphisms within cytokine genes are implicated in susceptibility to, and progression of, disease however
the published data are often conflicting. We undertook investigation of polymorphic alleles within cytokine genes in PTLD and non-
PTLD transplant cohorts to determine risk factors for disease.
METHODS: SSP-PCR was used to analyse single nucleotide polymorphism within tumour necrosis factor (TNF)-a, interleukin- 1, -6, -10
and lymphotoxin-a genes. The TNF-a levels were measured by standard enzyme-linked immuno-absorbant assay.
RESULTS: We show an association between variant alleles within the TNF-a promoter (1031C (P¼ 0.005)); 863A (P¼ 0.0001)
and TNF receptor I promoter regions (201T (P¼ 0.02)); 1135C (P¼ 0.03) with the development of PTLD. We also show an
association with TNF-a promoter haplotypes with haplotype-3 significantly increased (P¼ 0.0001) and haplotype-1 decreased
(P¼ 0.02) in PTLD patients compared to transplant controls. Furthermore, we show a significant increase (P¼ 0.02) in the level of
TNF-a in PTLD patient plasma (range 0–97.97 pgml1) compared to transplant controls (0–8.147 pgml1), with the highest levels
found in individuals carrying the variant alleles.
CONCLUSION: We suggest that genetic variation within TNF-a loci and the level of plasma cytokine could be used as a predictive risk
factor for the development of PTLD.
British Journal of Cancer (2009) 101, 1019 – 1027. doi:10.1038/sj.bjc.6605278 www.bjcancer.com
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Post-transplant lymphoproliferative disease (PTLD) is a potentially
lethal complication of iatrogenic immunosupression after solid
organ transplant (SOT) and bone marrow transplantation (Paya
et al, 1999; Nalesnik, 2002). It occurs in up to 10% of all transplant
recipients and in most cases is associated with Epstein–Barr virus
(EBV) infection, a gammaherpes virus that infects around 90% of
the adult population. On primary EBV infection the virus
establishes a life-long asymptomatic infection in circulating B
lymphocytes that are effectively controlled by EBV-specific
cytotoxic T lymphocytes (CTLs). In transplant recipients, however,
the immunosuppressive drug regimens used to control organ
rejection, suppress the function of EBV-specific CTLs and can lead
to the uncontrolled proliferation of EBV infected B lymphocytes
and tumour formation. Reduction of immunosupression, radio-
therapy, chemotherapy, surgery and monoclonal antibody-based
regimens (Swinnen et al, 1995; Choquet et al, 2006) are routinely
used to treat the disease on presentation of tumour, but even with
such treatment options the mortality rate is approximately 50%
(Opelz and Dohler, 2004; Choquet et al, 2007). More recently,
infusions of ex-vivo expanded EBV-specific CTLs to selectively
reconstitute EBV-specific immunity have proven useful in the
treatment and prevention of EBV-positive PTLD (Savoldo et al,
2006; Haque et al, 2007). Strategies to predict the impending
development of PTLD allowing early and effective intervention are
therefore assuming increasing importance. A raised EBV viral load
post transplant is one suggested marker of PTLD development
(Riddler et al, 1994; Davis et al, 2004); however, the published data
are contradictory with recent studies reporting that a high EBV
viral load does not predict PTLD development post transplant
(Benden et al, 2005; Sato et al, 2008; Wheless et al, 2008). More
robust strategies are therefore required especially with the advent
of promising new immunotherapies such as CTL infusion into the
clinical setting.
Cytokine networks interact in a dynamic way to regulate the
immune response, thus it is not surprising that variations in
cytokine levels have been correlated with susceptibility to disease
and disease progression (Brennan and McInnes, 2008; Feldmann,
2008). A fundamental issue of such studies is whether variation in
the level of a secreted cytokine is the primary cause for the disease
or a secondary downstream effect of the immune regulation
process. Investigation of cytokine gene polymorphisms is oneReceived 2 April 2009; revised 23 June 2009; accepted 27 July 2009
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approach of unravelling this issue and may provide a genetic
strategy for assigning a risk value to disease development.
Several studies have implicated polymorphisms within cytokine
genes with the risk of symptomatic primary EBV infection (Hurme
and Helminen, 1998; Helminen et al, 1999) and with the
development of EBV-associated tumours. Interleukin (IL)-18
variants, for example, have been associated with more aggressive
forms of nasopharyngeal carcinoma, whereas in contrast to a
protective role in EBV-associated infectious mononucleosis
(Helminen et al, 1999), the high producer IL-10 haplotype has
been associated with EBV-positive gastric cancer (Wu et al, 2002;
Pratesi et al, 2006). The low producer interferon gamma (IFN-g)
genotype has been implicated in EBV reactivation after stem cell
transplantation and with the development of PTLD after renal and
liver transplantation (VanBuskirk et al, 2001; Bogunia-Kubik et al,
2006; Lee et al, 2006). However, we recently investigated the low
producer IFN-g genotype in EBV-positive PTLD after various SOTs
and found no association with the development of disease
(Thomas et al, 2005). A more recent study investigating late-onset
PTLD showed an association with tumour growth factor-b1 and
IL-10 but not IFN-g genotypes (Babel et al, 2007). The reasons for
these observed differences are unknown but may, in part, be
because of the difference in type of organ transplant, type of PTLD
and/or small study cohorts.
Earlier studies have been criticised for use of small cohorts,
unmatched controls and investigation of single polymorphic alleles
(Ollier, 2004). Therefore, to resolve differences observed in the
literature with regard to cytokine gene polymorphisms in EBV-
positive PTLD, we analysed several cytokine gene and cytokine
receptor gene polymorphisms (alleles, genotypes and haplotypes)
in a large cohort of EBV-positive PTLD patients and appropriate
controls to determine correlations, if any, with the development of
disease.
MATERIALS AND METHODS
Study cohort
A cohort of EBV-associated PTLD patients was accrued as part of a
phase II multi-centre clinical trial detailed in Haque et al (2007).
Patients were recruited to the trial with informed written consent
from patients or guardians. The study was approved by the
Lothian Research Ethics Committee. Diagnosis of PTLD and its
classification were determined by histological examination and
EBV status determined by in situ hybridisation and immunohis-
tocehemisrty methods (detailed in Haque et al (2007)). A blood
sample was taken on diagnosis and plasma and peripheral blood
mononuclear cells (PBMC) were collected.
An anonymised control cohort of EBV sero-positive heart
transplant patients without any PTLD development was estab-
lished from an earlier study investigating EBV infection in heart
transplant patients (Hopwood et al, 2002). PBMC and plasma
samples were prepared in a similar manner to PTLD patients.
Healthy EBV sero-positive individuals were recruited as part of
an epidemiological study carried out at Edinburgh University.
Details for enrolment and serotyping have been published
elsewhere (Crawford et al, 2002, 2006). On recruitment, subjects
provided a blood sample for EBV serology. PBMC and plasma
samples were prepared as above.
Cytokine polymorphism PCR
DNA was extracted using the Easy-DNA kit (Invitrogen, Paisley,
UK) and amplified in 47 separate PCR reactions using primers
amplifying polymorphic regions within tumour necrosis
factor(TNF)-a, lymphotoxin (LT-a), IL-1-a, IL-6, IL-10, TNF
receptor(R)I, TNFRII, IL-1R and IL-10R genes (Supplementary
Table 1). Each primer mix also contained a set of control primers.
Between 60 and 80 ng DNA were amplified in a reaction mix
containing BioTaq DNA polymerase and reagents (Bioline,
London, UK): 1NH4 buffer; 1.5mM MgCl2; 200mM dNTPs and
0.35U Taq polymerase. Cycling parameters were staged as follows:
961C for 1min; 4 cycles of 961C for 20 s, 751C for 45 s, 721C for 25 s;
20 cycles of 961C for 25 s, 651C for 50 s, 721C for 30 s; 3 cycles of
961C for 30 s, 551C for 60 s, 721C for 90 s; 51C for 10min. The
resultant PCR product was visualised on a 2% agarose-ethidium
bromide gel under UV illumination.
Enzyme-linked immuno-absorbant assay (ELISA)
The level of human TNF-a was measured in plasma samples from
PTLD patients, non-PTLD transplant control patients and healthy
EBV sero-positive controls by quantitative ELISA (Mabtech, Nacka
Strand, Sweden) following the manufacturer’s instructions. Briefly,
wells were coated overnight with the monoclonal antibody TNF-a-I,
washed and blocked before the addition of quantified TNF
standards and patient plasma (undiluted). Plasma was allowed to
absorb for 2 h and was then washed. Bound TNF-a was detected
using the biotinylated monoclonal antibody to TNF-a-II and
streptavidin-alkaline phosphatase. The optical density at 405 nm
was measured after 30min incubation with the development
substrate p-nitrophenyl-phosphate (Sigma, Gillingham, UK).
Statistical methods
Each polymorphism was tested for Hardy–Weinberg disequili-
brium by comparing the observed allele frequency with the
expected frequency if equilibrium applied. Classical association
analysis was conducted to compare allele frequencies between the
groups of subjects (PTLD-positive and PTLD-negative post
transplant cohorts; PTLD positive and healthy control cohorts)
and tested using the Fisher’s exact or w2 test (this was not adjusted
for multiple testing). The Mann–Whitney U test and the one-way
ANOVA test were used to test for differences in the medians of
quantitative variables. Tests were two-tailed and a P-value o0.05
was considered significant. All statistical analysis was performed
using GraphPad PRISM software (GraphPad Software Inc., La Jolla,
CA, USA).
RESULTS
Known polymorphic alleles/regions from the TNF-a, LT-a, IL-1-a,
IL-6, IL-10, TNFRI, TNFRII, IL-1R and IL-10R (detailed in
Supplementary Table 1) were analysed in transplant patients with
(n¼ 45) or without (n¼ 65) EBV-positive PTLD (designated PTLD
and transplant control subject groups, respectively). Similar
analyses were also performed on a healthy adult EBV sero-positive
control cohort (n¼ 183). Both the transplant and healthy control
cohorts were compared with published frequencies (HapMap
Caucasian European (CEU) and CEU Geno frequencies; Pubmed
SNP database www.Ncbi.nlm.nih.gov) to assess any variation from
the normal expected frequencies: no major variation from
expected frequencies was noted. All polymorphic alleles were
found to be in Hardy–Weinberg equilibrium except for the single
nucleotide polymorphism at position 230 (A/G base change) in the
TNFRI promoter region within the transplant control group and
therefore individual analysis of this allele was not performed.
Increased frequency of the TNF promoter 1031C
and 863A variant alleles in PTLD subjects
A total of five polymorphic alleles within the TNF promoter region
(nucleotide positions relative to transcription start site 1031(T/C),
863(C/A), 857(C/T), 307(G/A) and 237(G/A)) were
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investigated. For the TNF promoter polymorphism at position
1031(T/C), we observed a significant increase in the frequency of
the rarer TNF 1031C allele in the PTLD subject group compared
with the non-PTLD transplant control group (37% vs 19%;
P¼ 0.005; Figure 1A; Table 1) and when compared with the
healthy control group (37% vs 23%; P¼ 0.01; Table 1). A
significant difference was also found in the genotype frequency
of this polymorphism with homozygous CC and heterozygous TC
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Figure 1 Allele frequencies of TNF promoter polymorphisms in transplant patients with and without PTLD. Allele frequencies (%) were calculated for
each polymorphic allele and statistical analysis performed using Fisher’s exact two-sided tests (significant P-value, Po0.05). Black bars (’) represent PTLD
transplant patients and white bars (&) transplant control patients. Significant P-value highlighted with asterisk (*). (A) Polymorphic alleles from the TNF-a
promoter; (B) polymorphic alleles from TNF receptor I; (C) polymorphic alleles from TNF receptor II.
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frequencies increased whereas homozygous TT frequencies were
decreased (CC: 9% PTLD subjects vs 3% transplant control
subjects; TC: 38% vs 32%; TT: 44% vs 65%, P¼ 0.01; CC: 3%,
TC: 40%, TT: 57%; P¼ 0.001 for healthy control subjects, Table 2).
Likewise for position TNF-863(C/A) we observed a significant
increase in the TNF-863A allele frequency in the PTLD transplant
group compared with the transplant control group (32% vs 11%;
P¼ 0.0001; Figure 1A; Table 1) and when compared with the
healthy control group (32% vs 15%; P¼ 0.0004; Table 1).
Comparison of the genotype frequencies between each group also
showed a significant difference for this polymorphism (CC: 44%
PTLD subjects vs 82% transplant control subjects; CA: 47% vs 15%;
AA: 9% vs 3%; P¼ 0.0003. CC: 73%, CA: 25%, AA: 2%, P¼ 0.0007;
Table 2). The remaining investigated TNF promoter polymorphisms,
at nucleotide positions 857(C/T), 307(G/A) and 237(G/A),
showed no differences in allele or genotype frequency between
transplant patients with or without PTLD or healthy controls
(Table 2).
From the investigated TNF promoter polymorphisms it is
possible to assign one out of six TNF promoter haplotypes,
detailed in Table 3 (Grutters et al, 2002). Haplotype-1 (TCCGG)
was under represented within the PTLD transplant group
compared with the transplant control group (62% vs 83%,
P¼ 0.02; OR¼ 2.6 (95% CI: 1.2–7.29)) whereas haplotype-3
(CACGG) was over represented (50% vs 14%, P¼ 0.0001;
OR¼ 0.16 (95% CI: 0.06–0.4; Table 3). Haplotype-3 remained
significantly over represented when compared with healthy
controls (50% vs 26%, P¼ 0.003; Table 3). Haplotypes-2, -4, -5
and -6 were comparable between all groups (Table 3).
Decreased frequency of the TNFRI promoter 201T and
increased frequency of 1135C alleles in PTLD subjects
Several polymorphisms within the TNFRII locus (exon-10 nucleo-
tide position þ 1663(A/G), þ 1668(T/G), þ 1690(C/T) and exon-6,
position þ 676(T/G)) and TNFRI promoter regions (nucleotide
positions 201(G/T), 230(A/G), 845(A/G), 839(G/A),
1135(T/C)) were investigated. Analysis of the TNFRI promoter
at position 201 showed a significant decrease in the frequency of
the 201T allele within the PTLD group compared with the
transplant control group (45% vs 29%, P¼ 0.02; Figure 1B;
Table 1). This was also true when the PTLD cohort was compared
with the healthy control group (47% vs 29%, P¼ 0.003; Table 1).
The TNFRI promoter 1135C allele was significantly increased in
the PTLD group compared with the transplant control group (71%
vs 57%, P¼ 0.03; Figure 1B; Table 1) and also when compared with
the healthy control group (71% vs 53%, P¼ 0.002; Table 1). The
TNFR1 promoter 845G allele was significantly increased in the
PTLD transplant group when compared with the healthy control
group but not when compared with the transplant control group
(51% vs 36%, P¼ 0.01; Table 1). No differences were observed for
TNFRII positions 1663, 1668, 1690, 676 or TNFRI promoter
positions 230, 845 and 839 (Figure 1B and C; Table 1).
Genotype frequencies of TNF receptors I and II polymorphisms
were also compared between the PTLD and transplant control
groups. Analysis of the TNFRI promoter at position 201 showed
a significant increase in the frequency of the 201GG genotype
and a decrease of the 201TT genotype in the PTLD group
compared with the transplant and healthy control groups
Table 1 Allele frequencies of the TNF-a´ promoter and TNF receptor polymorphisms in transplant patients with and without PTLD
Polymorphism Allele
Transplant subjects
without PTLD (n¼ 65)
freq (%)
Transplant subjects
with PTLD (n¼ 45)
freq (%) P-valuea
Healthy control subjects
(n¼183)
freq (%) P-valuea,b
TNF-a promoter
1031 T 81 63 0.005* 74 0.02*
C 19 37 23
863 C 89 68 0.0001* 85 0.004*
A 11 32 15
857 C 95 88 0.08 91 0.43
T 5 12 9
307 G 74 80 1 80 1
A 21 20 20
237 G 94 99 0.08 95 0.14
A 6 1 5
TNF receptor II
1663 A 36 48 0.56 49 0.91
G 48 52 51
1668 T 95 95 1 90 0.20
G 5 5 10
1690 C 37 40 0.67 38 0.81
T 63 60 62
676 T 78 79 1 71 0.18
G 22 21 29
TNF receptor I promoter
201 G 55 71 0.02* 53 0.003*
T 45 29 47
230b A 100 98 0.16 99 0.26
G 0 2 1
845 A 62 49 0.07 64 0.01*
G 38 51 36
839 G 98 98 1 98 0.66
A 2 2 2
1135 T 43 29 0.03* 47 0.002*
C 57 71 53
Abbreviations: freq¼ frequency; TNF¼ tumour necrosis factor. aFisher’s exact two-sided P-value (not adjusted for multiple testing). bComparison between post-transplant
lymphoproliferative disease (PTLD) and healthy control groups; *significant P-value, Po0.05.
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(GG: 47% vs 31%, TT: 4% vs 20%, P¼ 0.03 for PTLD vs transplant
controls; GG: 47% vs 26%, TT: 4% vs 20%, P¼ 0.006 for PTLD vs
healthy controls; Table 2). Similar analysis of the TNFRI promoter
position 1135 resulted in an observed decrease in the frequency
of the genotype 1135TT (4% vs 17%) and an increase in the
frequency of genotype 1135CC (47% vs 31%) within the PTLD
group compared with the transplant control group, however, this
did not reach significance (P¼ 0.06; Table 2). Significance was
reached when the PTLD transplant group was compared with
healthy controls (TT: 4% vs 20%, CC: 47% vs 25%, P¼ 0.005;
Table 2). A significant decrease in the GG genotype of 845 was
also noted between the PTLD transplant group and healthy
controls (22% vs 9%, P¼ 0.02; Table 2). No genotypic differences
were observed for TNFRII positions 1663, 1668, 1690, 676
or for TNFRI promoter positions 230, 845 and 839 (Table 2).
Determination of the TNFRI promoter haplotypes from nucleo-
tide positions 201, 230 and 845 results in five possible
haplotypes, detailed in Table 4. An increase in the frequency of
haplotype-1 (GAG) was observed in the PTLD group compared
with the transplant control group (80% vs 63%) and a decrease in
the frequency of haplotype-3 (TAA: 53% vs 69%, Table 4).
However, these differences did not reach statistical significance
(P¼ 0.05 and 0.11, respectively). However, both haplotypes-1 and
-3 were significantly different when the PTLD cohort was
compared with the healthy control cohort (GAG: 80% vs 63%,
P¼ 0.03; TAA: 53% vs 74%, P¼ 0.01; Table 4).
No difference in frequency was observed for any of the
polymorphic alleles, genotypes or haplotypes investigated from
the LT-a, IL-1, IL-6 and IL-10 loci and for those alleles from the
IL-1R1 and IL-10RI loci.
Table 2 Genotype frequencies of the TNF promoter, TNF receptor II and TNF receptor I promoter polymorphisms in transplant patients with and
without PTLD
Polymorphism Genotype
Transplant subjects
without PTLD (n¼ 65)
freq (%)
Transplant subjects
with PTLD (n¼ 45)
freq (%) P-valuea
Healthy control
subjects (n¼183)
freq (%) P-valuea,b
TNF-a promoter
1031 TT 65 44 0.01* 57 0.001*
TC 32 38 40
CC 3 9 3
863 CC 82 44 0.0003* 73 0.0007*
CA 15 47 25
AA 3 9 2
857 CC 89 78 0.18 84 0.63
CT 11 20 12
TT 0 20 2
307 GG 63 66 0.78 64 0.71
GA 32 27 32
AA 5 7 4
237 GG 88 98 0.08 40 0.10
GA 12 2 10
AA 0 0 0
TNF receptor II
1663 AA 18 20 0.39 26 0.53
AG 35 55 45
GG 31 25 29
1668 TT 91 90 0.89 80 0.14
TG 9 10 20
GG 0 0 0
1690 CC 11 16 0.25 18 0.75
CT 52 48 41
TT 37 36 41
676 TT 65 64 0.97 52 0.32
TG 28 29 38
GG 8 7 10
TNF receptor I promoter
201 GG 31 47 0.03* 26 0.006*
GT 48 49 54
TT 20 4 20
230 AA 100 96 0.08 98 0.25
AG 0 4 2
GG 0 0 0
845 AA 38 20 0.12 37 0.02*
AG 48 58 53
GG 14 22 9
839 GG 95 96 0.96 97 0.73
GA 5 4 3
AA 0 0 0
1135 TT 17 4 0.06 20 0.005*
TC 52 49 54
CC 31 47 25
Abbreviations: freq¼ frequency; TNF¼ tumour necrosis factor. aChi-square 3 2 contingency table (not adjusted for multiple testing). bComparison between post-transplant
lymphoproliferative disease (PTLD) and healthy control groups; *significant P-value, Po0.05.
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Increased plasma levels of TNF-a in patients with
EBV-positive PTLD
Polymorphisms within the TNF-a promoter regions have been
associated with variation in the level of cytokine produced by cells
(Koss et al, 2000). We therefore measured the levels of TNF-a in
the plasma of our patient groups EBV-positive PTLD (n¼ 25) and
non-PTLD transplant controls (n¼ 25) as well as in a cohort of
healthy EBV sero-positve controls (n¼ 25). Similar plasma TNF-a
levels were observed for the healthy EBV sero-positve and non-
PTLD transplant control groups (range 0–8.147 pgml1, median 0;
and 0–9.981 pgml1, median 0, respectively). In contrast, there
was a significant increase in the level of TNF-a in plasma obtained
from PTLD patients (range 0–97.97 pgml1, median 3.801;
P¼ 0.02; Figure 2). We next assessed the TNF-a levels in relation
to the polymorphic alleles and genotype of the PTLD patient
group. For the TNF promoter polymorphism at position 1031(T/
C), we assessed those with (C positive) and without (C negative)
the risk allele. A median value of 4.053pgml1 (range 0–66.69) was
observed for C-negative individuals compared with a median of
2.547 pgml1 (range 0–97.97) for C-positive individuals, however
this was not a significant difference (Figure 3A). Similarly, we
compared levels between the three genotypes and found no
significant differences in TNF-a levels (Figure 3A). No significant
difference in TNF-a levels for alleles and genotypes was observed
for TNF promoter polymorphisms at position 863(C/A), TNF
promoter haploytpes -1 and -3, or TNF receptor loci 201(G/T)
and 1135(T/C) (Figures 3B, 3C; Table 5).
DISCUSSION
In this study, we have assessed polymorphisms within the TNF,
LT-a, IL-1-a, IL-6 and IL-10 loci and their corresponding receptor
loci for evidence of an association with the development of
EBV-associated PTLD. The rarer alleles of the TNF promoter
polymorphisms at nucleotide positions 1031(C allele) and
863(A allele) were found to be significantly increased in EBV-
positive PTLD cases compared with non-PTLD transplant and
healthy controls. Likewise, genotypes containing the non-ancestral
allele were also significantly increased in the EBV-positive PTLD
cases compared with transplant and healthy control groups.
Furthermore, these polymorphic differences within the TNF
promoter region resulted in a significant increase of TNF
haplotype-3 (CACGG) and a decrease in TNF haplotype-1
Table 3 TNF promoter haplotypes in PTLD and control subjects
TNF promoter
polymorphism
Transplant
subjects
without
PTLD (n¼ 64)
Transplant
subjects
with PTLD
(n¼ 42) Odds ratio
Healthy
control
subjects
(n¼ 176) Odds ratio
Haplotype 1031 863 857 307 237 freq % freq % (95% CI) P-valuea freq % (95% CI) P-valuea,b
1 T C C G G 83 62 2.96 (1.2–7.29) 0.02* 76 0.52 (0.26–1.07) 0.08
2 T C C A G 36 31 1.25 (0.54–2.87) 0.67 37 0.76 (0.37–1.56) 0.59
3 C A C G G 14 50 0.16 (0.06–0.4) 0.0001* 26 2.91 (1.46–5.8) 0.003*
4 T C T G G 9 19 0.43 (0.14–1.37) 0.23 15 1.38 (0.57–3.26) 0.48
5 C C C G A 14 2 6.70 (0.81–55.10) 0.08 9 0.24 (0.03–1.90) 0.2
6 C C C G G 3 7 0.41 (0.06–2.62) 0.38 8 0.89 (0.24–3.25) 1
Abbreviations: CI¼ confidence interval; freq¼ frequency; TNF¼ tumour necrosis factor. Data are given as frequency with absolute numbers in parentheses. aFisher’s exact two-
sided P-value (not adjusted for multiple testing). bComparison between post-transplant lymphoproliferative disease (PTLD) and healthy control groups; *significant P-value,
Po0.05.
Table 4 TNF receptor I promoter haplotypes in PTLD
TNF receptor I promoter
polymorphism
Transplant
subjects without
PTLD
Transplant
subjects with
PTLD
Healthy
control
subjects
Haplotype 201 230 845 freq (%) freq (%) P-valuea freq (%) P-valuea,b
1 G A G 63 80 0.05 63 0.03*
2 G A A 31 33 0.83 29 0.59
3 T A A 69 53 0.11 74 0.01*
4 G G A 0 4 0.16 1 0.17
5 G G G 0 0 — 1 1
Abbreviations: freq¼ frequency; TNF¼ tumour necrosis factor. aFisher’s exact two-sided P-value (not adjusted for multiple testing). bComparison between post-transplant
lymphoproliferative disease (PTLD) and healthy control groups; *significant P-value, Po0.05.
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Figure 2 TNF-a levels in plasma from healthy controls and transplant
patients with and without PTLD. The TNF-a level in plasma was measured
by ELISA and the concentration estimated in relation to a set of known
standards. Median levels are highlighted by the black bars and statistical
analysis performed using the Mann–Whitney U test (significant P-value,
Po0.05).
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(TCCGG) in EBV-positive PTLD subjects compared with trans-
plant and healthy controls suggesting an important role for these
haplotypes in determining susceptibility to EBV-positive lympho-
ma after transplantation. Interestingly, the frequency of the TNFRI
promoter 1135C allele was also significantly increased and the
201T allele decreased in EBV-positive PTLD compared with
transplant and healthy controls. A corresponding increase in the
frequency of the homozygous 1135CC and a decrease in the
201TT genotypes were also observed for the EBV-positive PTLD
group confirming the importance of the TNF family of cytokines
and their receptors in the development of EBV-positive PTLD.
TNF is a member of the TNF family whose members function as
potent mediators of immune regulation and inflammation. The
TNF genes are located in the HLA class III region on chromosome
6p21.3 and are closely linked to the polymorphic HLA-B and -DR
regions (Nedwin et al, 1985). TNF cytokines bind to two cellular
receptors; TNFRI, which is widespread in many cells types and
activated by soluble ligand, and the TNFRII that is primarily
expressed on haemopoietic cells (Chan et al, 2000; Locksley et al,
2001). Both receptors are also shed and act as competitive soluble
TNF-binding proteins consequently affecting the levels of TNF. In
the case of TNF, ligand-receptor binding leads to the recruitment
of intracellular adaptor proteins that activate several signal
transduction pathways including the transcription factor NF-kB
and the apoptotic pathway through capsase 8 (Balkwill, 2006).
Many pathological situations are determined by the balance
between such survival and apoptotic signals. Therefore, gene
polymorphisms that alter this signalling process either through the
ligand or through the receptor are important.
The function of the TNF-863A variant highlighted in our PTLD
cohort has been widely investigated. The nucleotide change from C
to A has been shown to have a clear effect on the binding of the
NF-kB transcription complex to its DNA-binding domain. In
particular, the affinity of the NFkB p50–p50 heterodimer, which
acts as a transcriptional repressor when bound to the TNF
promoter, is significantly decreased for the 863A variants
(Udalova et al, 2000). Decreased binding is thought to result in
inadequate downregulation of TNF gene expression and therefore
increased TNF production. As yet, there is no comparable
molecular data for the TNF-1031C allele (however there is some
degree of linkage between the 1031 and 863 alleles) or for the
TNFRI promoter 201T and 1135C alleles.
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Figure 3 TNF-a levels in plasma from PTLD patients in relation to
genetic variance. The level of TNF-a was estimated and assessed in relation
to variant allele status (negative or positive), genotype or haplotype for
position –1031(T/C) (A), 863(C/A) (B) and for the TNF-a promoter
haplotype (C). Median levels are highlighted by the black bars and statistical
analysis performed using the Mann–Whitney U test or one-way ANOVA
test (significant P-value, Po0.05).
Table 5 TNF-a levels in plasma of PTLD patients; genetic subgroup
analysis
Levels of TNF-a in Plasma
Polymorphic loci Number
Median
(range, pgml1) P-valuea
TNF 1031
C allele negative 11 4.053 (0–66.69)
0.85
C allele positive 14 2.547 (0–97.97)
TT 11 4.053 (0–66.69)
0.56
TC 10 0.645 (0–97.97)
CC 4 10.06 (0–30.34)
TNF 865
A allele negative 11 4.053 (0–66.69)
0.85
A allele positive 14 2.547 (0–97.97)
CC 11 4.053 (0–66.69)
0.96CA 12 2.547 (0–97.97)
AA 2 6.088 (0–12.18
TNF haplotype
Haplotype-3 positive 13 3.801 (0–97.97)
0.68
Haplotype-3 negative 11 4.053 (0–66.69)
Haplotype-1 positive 14 3.378 (0–66.69)
0.53
Haplotype-1 negative 10 5.997 (0–97.97)
TNFR 201
T allele negative 13 4.427 (0–97.97)
0.31
T allele positive 12 1.477 (0–30.34)
GG 13 4.427 (0–97.97)
0.27GT 10 0 (0–17.52)
TT 2 16.64 (0–13.69)
TNFR 1135
C allele negative 2 16.64 (0–30.34) —
C allele positive 23 3.801 (0–97.97)
TT 2 16.64 (0–30.34)
0.27TC 10 0 (0–17.52)
CC 13 4.427 (0–97.97)
aMann–Whitney U Test or one-way ANOVA (Significant P-value, Po0.05).
TNF polymorphism and PTLD
KA McAulay et al
1025
British Journal of Cancer (2009) 101(6), 1019 – 1027& 2009 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
Analysis of TNF-a levels in plasma from our cohorts
showed a significant difference in levels between transplant
controls and EBV-positive PTLD patients in general with
higher TNF-a levels detected in the EBV-positive PTLD group.
We did not detect a significant difference in TNF-a levels when we
assessed the effect of the genetic variants within the PTLD cohort
however there was a slight trend for higher TNF-a levels in the
variant groups (Figure 3). This trend may become stronger with a
larger cohort of PTLD individuals carrying the variant allele.
Determining TNF-a levels in variant positive and negative
individuals after transplant and before development of disease
would provide further information on the predictive value of
TNF-a levels.
Interestingly, the presence of the TNF-863A allele has also been
positively associated with susceptibility to B-cell malignancies
(non-Hodgkin’s lymphomas) in the general population (Spink
et al, 2006). Possession of specific alleles that act to increase TNF
expression may therefore be central to the pathogenesis and
susceptibility to lymphoid disease. Indeed, TNF-based mechan-
isms, such as direct DNA damage, anti-apoptotic activity and
induction of cytokines, have been implicated in several cancers
(Balkwill, 2006).
In summary, we have shown an association between variant
alleles of the TNF promoter and the subsequent TNF promoter
haplotype with the development of EBV-positive PTLD (although
it has to be noted that this data set was not adjusted for multiple
testing and so type 1 error cannot be completely ruled out).
We have also shown that TNF-a levels are significantly higher in
EBV-positive PTLD patients. However, there remains a group of
EBV-positive PTLD patients who do not carry these alleles,
genotypes or haplotypes, perhaps indicating that these poly-
morphisms are not independently functional and that other, as yet,
unidentified variants are in linkage disequlibrium with these loci.
These data require confirmation in a second, larger sized cohort to
be certain of an association (power calculations based on this pilot
study indicate a PTLD and non-PTLD transplant group size of 105
subjects would provide 80% power, 95% CI, OR¼ 2.5) and further
analysis of soluble TNF levels may offer some information on the
functional activity of these polymorphic alleles. Nevertheless, the
genotypic evidence for the involvement of TNF in EBV-positive
PTLD presented here provides further information for identifying
those most at risk.
ACKNOWLEDGEMENTS
Statistical advice was obtained from Dr Craig Higgins (Department
of Epidemiology and Population Health, London School of
Hygiene and Tropical Medicine, London) and Colette Smith
(Research Department of Infection and Population Health, UCL
Medical School, London). Thanks also to Dr Anna Lagan, National
Heart and Lung Institute, Imperial College, London, for help with
cytokine SSP-PCR. This work was supported by grants from CRUK
(C307/A3869) and MRC (UK) (G 9826804).
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Babel N, Vergopoulos A, Trappe R, Oertel S, Hammer MM, Karaianov S,
Schneider N, Riess H, Papp-Vary M, Neuhaus R, Gondek L, Volk H,
Reinke P (2007) Evidence for genetic susceptibility towards development
of posttransplant lymphoproliferative disorder in solid organ recipients.
Transplantation 84: 387–391
Balkwill F (2006) TNF-alpha in promotion and progression of cancer.
Cancer Metastasis Rev 25: 409–416
Benden C, Aurora P, Burch M, Cubitt D, Lloyd C, Whitmore P, Neligan SL,
Elliott MJ (2005) Monitoring of Epstein-Barr viral load in pediatric heart
and lung transplant recipients by real-time polymerase chain reaction.
J Heart Lung Transplant 24: 2103–2108
Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A (2006) The
presence of IFNG 3/3 genotype in the recipient associates with increased
risk for Epstein-Barr virus reactivation after allogeneic haematopoietic
stem cell transplantation. Br J Haematol 132: 326–332
Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in
rheumatoid arthritis. J Clin Invest 118: 3537–3545
Chan FK-M, Siegel RM, Lenardo MJ (2000) Signaling by the TNF receptor
superfamily and T cell homeostasis. Immunity 13: 419–422
Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P,
Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN,
Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A,
Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P,
Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N (2006)
Efficacy and safety of rituximab in B-cell post-transplantation lympho-
proliferative disorders: results of a prospective multicenter phase 2
study. Blood 107: 3053–3057
Choquet S, Oertel S, Leblond V, Riess H, Varoqueaux N, D+Aˆrken B,
Trappe R (2007) Rituximab in the management of post-transplantation
lymphoproliferative disorder after solid organ transplantation: proceed
with caution. Ann Hematol 86: 599–607
Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams
H, Harrison N, Reid S, Conacher M, Douglas J, Swerdlow AJ (2006) A
cohort study among university students: identification of risk factors for
Epstein-Barr virus seroconversion and infectious mononucleosis. Clin
Infect Dis 43: 276–282
Crawford DH, Swerdlow AJ, Higgins CD, McAulay K, Harrison N, Williams
H, Britton K, Macsween KF (2002) Sexual history and Epstein-Barr virus
infection. J Infect Dis 186: 731–736
Davis JE, Sherritt MA, Bharadwaj M, Morrison LE, Elliott SL, Kear LM,
Maddicks-Law J, Kotsimbos T, Gill D, Malouf M, Falk MC, Khanna R,
Moss DJ (2004) Determining virological, serological and immunological
parameters of EBV infection in the development of PTLD. Int Immunol
16: 983–989
Feldmann M (2008) Many cytokines are very useful therapeutic targets in
disease. J Clin Invest 118: 3533–3536
Grutters JC, Sato H, Pantelidis P, Lagan AL, McGrath DS, Lammers JW, van
den Bosch JMM, Wells AU, du Bois RM, Welsh KI (2002) Increased
frequency of the uncommon tumor necrosis factor -857T allele in British
and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 165:
1119–1124
Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P,
Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D,
MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH (2007)
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation
lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
Blood 110: 1123–1131
Helminen M, Lahdenpohja N, Hurme M (1999) Polymorphism of the
interleukin-10 gene is associated with susceptibility to Epstein-Barr virus
infection. J Infect Dis 180: 496–499
Hopwood PA, Brooks L, Parratt R, Hunt BJ, Maria B, Alero
TJ, Magdi Y, Crawford DH (2002) Persistent Epstein-Barr virus infection:
unrestricted latent and lytic viral gene expression in healthy
immunosuppressed transplant recipients1. Transplantation 74:
194–202
Hurme M, Helminen M (1998) Polymorphism of the IL-1 gene complex in
Epstein-Barr virus seronegative and seropositive adult blood donors.
Scand J Immunol 48: 219–222
Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP (2000) Cytokine
(TNFa, LTa and IL-10) polymorphisms in inflammatory bowel diseases
and normal controls: differential effects on production and allele
frequencies. Genes Immun 1: 185–190
TNF polymorphism and PTLD
KA McAulay et al
1026
British Journal of Cancer (2009) 101(6), 1019 – 1027 & 2009 Cancer Research UK
G
e
n
e
tic
s
a
n
d
G
e
n
o
m
ic
s
Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP,
Caldwell Y, Scott JD, Goss JA (2006) Use of cytokine polymorphisms and
Epstein-Barr virus viral load to predict development of post-transplant
lymphoproliferative disorder in paediatric liver transplant recipients.
Clin Transplant 20: 389–393
Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF
receptor superfamilies: integrating mammalian biology. Cell 104:
487–501
Nalesnik MA (2002) Clinicopathologic characteristics of post transplant
lymphoproliferative disorders. Recent Results Cancer Res 159: 9–18
Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica
D, Goeddel DV, Gray PW (1985) Human lymphotoxin and tumor
necrosis factor genes: structure, homology and chromosomal localiza-
tion. Nucleic Acids Res 13: 6361–6373
Ollier WER (2004) Cytokine genes and disease susceptibility. Cytokine 28:
174–178
Opelz G, Dohler B (2004) Lymphomas after solid organ transplantation: a
collaborative transplant study report. Am J Transplant 4: 222–230
Paya C, Fung J, Nalesnik M, Kieff E, Green M, Gores G, Habermann T,
Wiesner R, Swinnen L, Woodle E, Bromberg J (1999) Epstein-Barr virus-
induced posttransplant lymphoproliferative disorders. Transplantation
68: 1517–1525
Pratesi C, Bortolin M, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R,
Guidoboni M, Franchin G, Barzan L, Zanussi S, Caruso C,
De Paoli P (2006) Interleukin-10 and interleukin-18 promoter poly-
morphisms in an Italian cohort of patients with undifferentiated
carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55:
23–30
Riddler SA, Breinig MC, McKnight JL (1994) Increased levels of circulating
Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV
nuclear antigen antibody responses are associated with the development
of posttransplant lymphoproliferative disease in solid-organ transplant
recipients. Blood 84: 972–984
Sato T, Fujieda M, Tanaka E, Miyamura M, Chikamoto H, Hisano M,
Akioka Y, Ishiura Y, Dohno S, Maeda A, Hattori M, Wakiguchi H (2008)
Monitoring of Epstein-Barr virus load and antibody in pediatric renal
transplant patients. Paediatr Int 50: 454–458
Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF,
Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ,
Brenner MK, Rooney CM, Heslop HE (2006) Treatment of solid organ
transplant recipients with autologous Epstein Barr virus-specific
cytotoxic T lymphocytes (CTLs). Blood 108: 2942–2949
Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ (2006)
Association between non-Hodgkin lymphoma and haplotypes in the TNF
region. Br J Haematol 133: 293–300
Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI (1995) Aggressive
treatment for postcardiac transplant lymphoproliferation. Blood 86:
3333–3340
Thomas R, McAulay K, Higgins C, Wilkie G, Crawford D (2005) Interferon
gamma polymorphisms in posttransplant proliferative disease. Blood
106: 1502–1503
Udalova IA, Richardson A, Denys A, Smith C, Ackerman H, Foxwell B,
Kwiatkowski D (2000) Functional consequences of a polymorphism
affecting NF-kappa B p50-p50 binding to the TNF promoter region. Mol
Cell Biol 20: 9113–9119
VanBuskirk A, Malik V, Xia D, Pelletier R (2001) A gene polymorphism
associated with posttransplant lymphoproliferative disorder. Transplant
Proc 33: 1834
Wheless SA, Gulley ML, Raab-Traub N, McNeillie P, Neuringer IP, Ford HJ,
Aris RM (2008) Post-transplantation lymphoproliferative disease:
Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit
Care Med 178: 1060–1065
Wu MS, Huang SP, Chang YT, Shun CT, Chang MC, Lin MT, Wang HS, Lin
JT (2002) Tumour necrosis factor-a´ and interleukin-10 promoter
polymorphisms in Epstein-Barr virus associated gastric carcinoma.
J Infect Dis 185: 106–109
TNF polymorphism and PTLD
KA McAulay et al
1027
British Journal of Cancer (2009) 101(6), 1019 – 1027& 2009 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
